Congratulations to the finalists of the Databricks #GenerativeAI Startup Challenge, which recognizes some of the most innovative startups harnessing the power of GenAI on the Databricks Data Intelligence Platform. These companies are doing groundbreaking work to solve real-world customer problems: - ChipStack: Optimizes chip design and verification processes, reducing time to market - Flagler Health: Improves health outcomes by streamlining processes within healthcare settings - Orby AI: Delivers an AI agent platform to automate enterprise processes and enhance efficiency - Vevo Therapeutics: Uses Mosaic AI to map how drug molecules interact with cells from patients Learn more about the finalists: https://dbricks.co/4fN1JTI
Vevo Therapeutics
生物技术研究
We are combining in vivo data and AI to find better targets and drugs that can treat more patients.
关于我们
Vevo Therapeutics is a biotechnology company using its in vivo drug discovery platform and next generation AI models to uncover better drugs for more patients. The company’s Mosaic platform is the first to make in vivo data generation scalable, with single-cell precision, to capture in vivo context of disease at the first step of drug discovery and to better represent patient diversity in drug response over current in vitro assays. Vevo is using Mosaic to build the world’s largest in vivo atlas of how drugs interact with patient cells and training AI models on its data to find novel targets and drugs undetectable by other technologies. Located in San Francisco, CA, Vevo was founded by a team of inventors and thought leaders who have discovered drugs for “undruggable” targets and invented novel methods in genomics, computational biology, and chemistry. Vevo is backed by leading investors at the intersection of life sciences and technology, including General Catalyst, Wing Venture Capital, Mubadala Capital, AIX Ventures, and Camford Capital. Learn more at www.vevo.ai.
- 网站
-
https://www.vevo.ai/
Vevo Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 类型
- 私人持股
- 创立
- 2022
Vevo Therapeutics员工
动态
-
Congratulations to the finalists of the Databricks #GenerativeAI Startup Challenge, which recognizes some of the most innovative startups harnessing the power of GenAI on the Databricks Data Intelligence Platform. These companies are doing groundbreaking work to solve real-world customer problems: - ChipStack: Optimizes chip design and verification processes, reducing time to market - Flagler Health: Improves health outcomes by streamlining processes within healthcare settings - Orby AI: Delivers an AI agent platform to automate enterprise processes and enhance efficiency - Vevo Therapeutics: Uses Mosaic AI to map how drug molecules interact with cells from patients Learn more about the finalists: https://dbricks.co/4fN1JTI
-
-
Thank you Michael Eisenstein and Nature Magazine. “To test potential new oncology agents, Vevo scientists are generating chimeric tumors that can capture a broad spectrum of tumor biology in a single go. The company’s mosaic platform consists of cells from tens or hundreds of different patient models that are implanted into mice to generate a patient- or cell-line derived xenograft model. This approach builds on academic work from cofounders Johnny Yu, Hani Goodarzi and Kevan Shokat at the University of Califorina at San Francisco. Mosaic-based experiments can reveal how different combinations of mutations influence response or resistance to various potential therapies. Alidoust notes that their library of patient samples is genetically diverse and encompasses many tissue types and driver mutations. “Every time you’re running a mosaic experiment, you are testing a drug against around one-third of the genetic backgrounds that are available,” he says. This approach could thus help identify specific subgroups of patients who, for example, might be the best fit for a particular regimen.”
Indeed: finding and optimizing drugs in rudimentary in vitro assays is like “finding the best sprinter and sending them to run a marathon” Thank you Nature Biotechnology (Nature Magazine) and Michael Eisenstein for featuring our work in this great piece. As Michael elegantly outlines, we at Vevo Therapeutics believe that the root of many failures in the clinic is how we model disease preclinically. We need better disease models that capture the fact that disease happens in a living organism and in extremely heterogeneous patients that can not be reduced to a single driver gene or protein target. Disease models that can capture this at scale will not only lead to better therapeutics but also unlock new business models that can change the economics of drug discovery. https://lnkd.in/gYnEuvVg Johnny Yu, Hani Goodarzi, Daniele Merico, Shreshth Gandhi
-
Vevo ?? Amazon Web Services (AWS)
Last year, we were one of the 20 startups (of 1200+) that were selected to be part of Amazon Web Services (AWS)'s Generative AI startup cohort. This year, we are excited to support AWS in welcoming more startups to the group. Thanks for the shout-out from our friends at AWS in this exciting announcement!
AWS Announces $230 Million Commitment for Generative AI Startups
press.aboutamazon.com